Apolipoprotein(a) [apo(a)] kringle domain / apo(a)-apoB100 interaction

Class

Oral small-molecule Lp(a) formation inhibitor

Pathway

Binds apo(a) kringle domains to block the noncovalent apo(a)-apoB100 interaction required to assemble Lp(a) particles, without cross-reacting with plasminogen

Lipoprotein(a), or Lp(a), is a low-density-lipoprotein-like particle distinguished by an additional protein, apolipoprotein(a) [apo(a)], attached to apolipoprotein B100 (apoB100). Genetic studies have established that elevated circulating Lp(a) is a causal, largely inherited risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease, independent of LDL cholesterol. Unlike LDL, Lp(a) levels are not meaningfully altered by diet, exercise, or most existing lipid-lowering drug classes, motivating interest in agents that act earlier, at the point of particle assembly. Lp(a) is formed when apo(a), synthesized in the liver, binds apoB100-containing particles through specialized protein modules called kringle domains. This mechanism describes an oral small molecule designed to occupy those kringle domains and physically block the interaction between apo(a) and apoB100, preventing new Lp(a) particles from being assembled and released into circulation, rather than clearing particles once formed. Because the kringle domains of apo(a) closely resemble those of plasminogen, a protein central to blood clot breakdown, a key design goal for this class is selectivity: blocking the apo(a)-apoB100 interaction without interfering with plasminogen's normal role in fibrinolysis. This mechanism is relevant broadly to cardiovascular risk reduction in individuals with genetically elevated Lp(a).